Pasar al contenido principal

MEJORANDO TRATAMIENTOS DE FRONTERA EN ONCOLOGIA Y CAMPOS RELACIONADOS USANDO MODELOS MATEMATICOS Y DATOS BIOMEDICOS

PID2022-142341OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE CASTILLA-LA MANCHA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Understanding the role of B cells in CAR T-cell therapy in leukemia through a mathematical model

  • Serrano, Sergio
  • Barrio, Roberto
  • Martínez Rubio, Álvaro
  • Belmonte Beitia, Juan
  • Pérez-García, Víctor M.
Chimeric Antigen Receptor T (CAR-T) cell therapy has been proven to be successful against different leukaemias and lymphomas. This paper makes an analytical and numerical study of a mathematical model describing the competition of CAR-T, leukaemias tumor and B cells. Considering its significance in sustaining anti-CD19 CAR T-cell stimulation, we integrate a B-cell source term into the model. Through stability and bifurcation analyses, we reveal the potential for tumor eradication contingent on the continuous influx of B-cells, uncovering a transcritical bifurcation at a critical B-cell input. Additionally, we identify an almost heteroclinic cycle between equilibrium points, providing a theoretical basis for understanding disease relapse. Analyzing the oscillatory behavior of the system, we approximate the time-dependent dynamics of CAR T-cells and leukemic cells, shedding light on the impact of initial tumor burden on therapeutic outcomes. In conclusion, our study provides insights into CAR T-cell therapy dynamics for acute lymphoblastic leukemias, offering a theoretical foundation for clinical observations and suggesting avenues for future immunotherapy modeling research.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A mathematical model of CAR-T cell therapy in combination with chemotherapy for malignant gliomas

  • Sinelshchikov, Dmitry I.
  • Belmonte Beitia, Juan
  • Italia, Matteo
This article may be downloaded for personal use only. Any other use requires prior permission of the author and AIP Publishing. This article appeared in Chaos 35, 063104 (2025) and may be found at https://doi.org/10.1063/5.0260252., Malignant gliomas (MGs) are among the most aggressive primary brain tumors, characterized by a high degree of resistance to therapy and poor prognosis. In this work, we develop a mathematical model to investigate the dynamics of MG under the combined effects of chemotherapy and chimeric antigen receptor cell therapy. The proposed model is a five-dimensional dynamical system incorporating impulsive inputs that correspond to the clinical administration of chemotherapy and immunotherapy. We demonstrate the non-negativity of solutions for non-negative initial conditions, ensuring the biological relevance of the model. We show that if we apply both therapies only once, the trajectories are attracted to an invariant surface corresponding to the tumor carrying capacity. Conversely, under constant administration of both treatments, we identify parameter ranges in which tumor eradication is achievable. Furthermore, we numerically study various treatment combinations to determine optimal protocols at the population level. To this end, we generate a cohort of 104 virtual patients with model parameters sampled uniformly within clinically relevant ranges and carry out in silico trials. Our findings indicate that tumor growth rate, chemotherapy efficacy, and tumor-induced immunosuppression are the key determinants of survival outcomes. We believe that our results provide new theoretical insights into treatment optimization and offer a framework for refining the design of clinical trials for MG therapies., This article is part of the research project SBPLY/23/180225/000041, funded by the EU through the ERDF and by the JCCM through INNOCAM, Ministerio de Ciencia e Innovación, Spain (doi:10.13039/501100011033) and University of Castilla-La Mancha Grant (No. 2022-GRIN-34405) (Applied Science Projects within the UCLM research programme). M.I and J.B.-B. were partially supported by European Regional Development Fund (ERDF A way of making Europe) under Grant No. PID2022-142341OB-I00. D.S. is partially supported by H2020-MSCACOFUND-2020-101034228-WOLFRAM2 and PIBA-2024-1-0016., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Mathematical Model of CAR T-Cell Therapy for a B-Cell Lymphoma Lymph Node

  • Sabir, Soukaina
  • León-Triana, Odelaisy
  • Serrano, Sergio
  • Barrio, Roberto
  • Pérez-García, Victor M.
CAR T-cell therapies have demonstrated significant success in treating B-cell leukemia in children and young adults. However, their effectiveness in treating B-cell lymphomas has been limited in comparison to leukemia. In this paper we present a mathematical model that elucidates the dynamics of diffuse large B-cell lymphoma and CAR T-cells in a lymph node. The mathematical model aids in understanding the complex interplay between the cell populations involved and proposes ways to identify potential underlying dynamical causes of treatment failure. We also study the phenomenon of immunosuppression induced by tumor cells and theoretically demonstrate its impact on cell dynamics. Through the examination of various response scenarios, we underscore the significance of product characteristics in treatment outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression

  • Molina, Oscar|||0000-0001-7585-4519
  • Ortega-Sabater, C.
  • Thampi, Namitha|||0000-0001-6166-583X
  • Fernández Fuentes, Narcís|||0000-0002-6421-1080
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Bueno, Clara|||0000-0003-1442-6216
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Granada, Isabel|||0000-0002-4275-0104
  • Campos, Diana
  • Giménez, Carles
  • Boer, Judith M.|||0000-0003-4848-7789
  • den Boer, Monique L.
  • Calvo, Gabriel F.|||0000-0002-3623-236X
  • Camós, Mireia|||0000-0003-3658-7942
  • Fuster, José Luis|||0000-0002-4881-9440
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Ballerini, Paola
  • Locatelli, Franco|||0000-0002-7976-3654
  • Mullighan, Charles G.|||0000-0002-1871-1850
  • Spierings, Diana C.J.|||0000-0001-8403-474X
  • Foijer, Floris|||0000-0003-0989-3127
  • Pérez-García, Víctor M.|||0000-0002-6575-495X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Chromosomal instability (CIN) lies at the core of cancer development leading to aneuploidy, chromosomal copy-number heterogeneity (chr-CNH) and ultimately, unfavorable clinical outcomes. Despite its ubiquity in cancer, the presence of CIN in childhood B-cell acute lymphoblastic leukemia (cB-ALL), the most frequent pediatric cancer showing high frequencies of aneuploidy, remains unknown. Here, we elucidate the presence of CIN in aneuploid cB-ALL subtypes using single-cell whole-genome sequencing of primary cB-ALL samples and by generating and functionally characterizing patient-derived xenograft models (cB-ALL-PDX). We report higher rates of CIN across aneuploid than in euploid cB-ALL that strongly correlate with intraclonal chr-CNH and overall survival in mice. This association was further supported by in silico mathematical modeling. Moreover, mass-spectrometry analyses of cB-ALL-PDX revealed a "CIN signature" enriched in mitotic-spindle regulatory pathways, which was confirmed by RNA-sequencing of a large cohort of cB-ALL samples. The link between the presence of CIN in aneuploid cB-ALL and disease progression opens new possibilities for patient stratification and offers a promising new avenue as a therapeutic target in cB-ALL treatment.